First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid

被引：0
|
作者：
Lin, F. [1 ]
Huang, Y. [2 ]
Huang, Y. [2 ]
Lu, Y. [2 ]
Rao, X. [3 ]
Wang, X. [2 ]
Wang, F. [2 ]
Huang, X. [2 ]
机构：
[1] Tongji Univ, Shanghai East Hosp, Med Oncol, Shanghai, Peoples R China
[2] Hangzhou Adcoris Biopharma Co Ltd, Translat Med, Hangzhou, Peoples R China
[3] Nanchang Univ, Affiliated Hosp 1, Med Oncol, Nanchang, Jiangxi, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.08.274
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
335P
引用
收藏
页码：S354 / S355
页数：2
相关论文
共 50 条
  • [1] Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors
    Miao, Zhenwei
    Lin, Fengjuan
    Rao, Xi
    Huang, Yong
    Wang, Feng
    Lu, Yao
    Huang, Xiuying
    Huang, Yunsheng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Phase I study of ZV0203, a first in class pertuzumab ADC, in patients with HER2+advanced solid tumors
    Lin, F.
    Huang, Y.
    Lu, Y.
    Rao, X.
    Wang, F.
    Huang, Y.
    Huang, X.
    ANNALS OF ONCOLOGY, 2023, 34 : S365 - S365
  • [3] First-in-human study of DP303c, a HER2-targeted antibody-drug conjugate in patients with HER2 positive solid tumors
    Zhang, Jian
    Du, Yiqun
    Meng, Yanchun
    Liu, Xiaojun
    Mu, Yuxin
    Liu, Yunpeng
    Shi, Yehui
    Wang, Jufeng
    Zang, Aimin
    Gu, Shanzhi
    Liu, Tianshu
    Zhou, Huan
    Guo, Hongqian
    Xiang, Silong
    Zhang, Xialu
    Wu, Suqiong
    Qi, Huanhuan
    Li, Mengke
    Hu, Xichun
    NPJ PRECISION ONCOLOGY, 2024, 8 (01)
  • [4] YL201, a novel B7H3-targeting antibody-drug conjugate (ADC), in patients (pts) with advanced solid tumors: Results from a first-in-human phase I study
    Zhao, H.
    Ma, Y.
    Meng, X.
    Wu, L.
    Fan, Y.
    Zheng, Y.
    Liu, Z.
    Ji, Y.
    Lv, D.
    Luo, S.
    Sommerhalder, D.
    Fu, S.
    Huang, Y.
    Yang, Y.
    Fang, W.
    Zhao, Y.
    Wang, Y.
    Chin, S.
    Xue, T.
    Zhang, L.
    ANNALS OF ONCOLOGY, 2024, 35 : S485 - S485
  • [5] EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors
    Aggarwal, Charu
    Azzoli, Christopher G.
    Spira, Alexander I.
    Solomon, Benjamin J.
    Le, Xiuning
    Rolfo, Christian
    Planchard, David
    Felip, Enriqueta
    Wu, Yi-Long
    Ahn, Myung-Ju
    Seiwert, Tanguy Y.
    Goto, Koichi
    Azaro, Analia
    Lissa, Delphine
    Hamid, Oday
    McGrath, Lara
    Maudsley, Rhiannon
    Arnaldez, Fernanda I.
    Grenga, Italia
    Massarelli, Erminia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Preliminary results from a first-in-human trial of AMT-116, a topoisomerase I inhibitor containing antibody-drug conjugate (ADC), in patients with advanced solid tumors
    Coward, Jim
    Kichenadasse, Ganessan
    Park, John J.
    Parakh, Sagun
    Richardson, Gary Edward
    Voskoboynik, Mark
    Powderly, John D., II
    Song, Zhengbo
    Liu, Shutong
    Huang, Yaling
    Liu, Shu-Hui
    Meng, Xun
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] First-In-Human Phase 1/2 Trial of Anti-AXL Antibody-Drug Conjugate (ADC) Enapotamab Vedotin (EnaV) in Advanced NSCLC
    Ramalingam, S.
    Lopez, J.
    Mau-Sorensen, M.
    Thistlethwaite, F.
    Piha-Paul, S.
    Gadgeel, S.
    Drew, Y.
    Janne, P.
    Mansfield, A.
    Chen, G.
    Forssmann, U.
    Johannsdottir, H.
    Pencheva, N.
    Ervin-Haynes, A.
    Vergote, I.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S209 - S209
  • [8] A phase I study of A166, a novel anti-HER2 antibody-drug conjugate (ADC), in patients with locally advanced/metastatic solid tumors
    Lopez, Diana M.
    Barve, Minal
    Wang, Judy
    Bullock, Andrea J.
    Pectasides, Eirini
    Vaishampayan, Ulka
    Spira, Alexander I.
    Ulahannan, Susanna
    Patnaik, Amita
    Sanborn, Rachel E.
    Cicic, Dragan
    Ang, Qiuqing
    Bergonio, Gregory
    Ahnert, Jordi Rodon
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (12)
  • [9] A phase lb, first-in-human, dose escalation and expansion study of XMT-1522, a novel antibody-drug conjugate (ADC) directed against HER2, in patients with advanced breast cancer and other advanced tumors expressing HER2.
    Burris, Howard A.
    Barve, Minal A.
    Hamilton, Erika Paige
    Bardia, Aditya
    Soliman, Hatem Hussein
    Jarlenski, Donna
    Mosher, Rebecca
    Bergstrom, Donald Alan
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [10] First-in-human phase I study of ALT-P7, a HER2-targeting antibody-drug conjugate in patients with HER2-positive advanced breast cancer.
    Park, Yeon Hee
    Ahn, Hee Kyung
    Kim, Ji-Yeon
    Ahn, Jin Seok
    Im, Young-Hyuck
    Kim, Seol-Hee
    Lee, Sunbae
    Chung, Hye-Shin
    Park, Soon Jae
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345